Welcome to
BGI Australia

Next Generation Sequencing Research Grant

Call for Application is now closed.

Thank you all the applicants for submitting applications. During the past few weeks we have received a large volume of applications via the online portal and email. We sincerely appreciate your interest and effort in the submitting your application. Within the next  two weeks all applications will be assessed by a committee of MGI/Micromon product managers, technical specialists, laboratory managers, and researchers to evaluate their eligibility, feasibility, technical capability, research merit, academic influence and commercial value.  The shortlisted applicants may be contacted for further clarifications or additional information in due course. Through a meticulous assessment process evaluating these criteria the committee will select three successful applicants, with whom we will mutually establish a collaborative research agreement that addresses sample shipping, data ownership, and IP issues as appropriate to each project. The results will be communicated individually with the applicants at the end of the assessment process. Due to the large volume of applications received and their high competitiveness, we have to extend the assessment process for a few more days.  We will announce the winners on BGI Australia website on 24th July 2019. Please keep up the anticipation!


Grant Program Document

You may download the full grant program document below. In the meantime if you have any other grant related questions about your application submitted please email with the subject “NGS Grant Program 2019” to bgi-australia@genomics.cn.

Grant program document
image6

First Commercial MGISEQ-2000 Genetic Sequencer in Australia

MGI, a division of BGI Group, announced that Micromon Genomics is the first Australian commercial user of its high-throughput genetic sequencer MGISEQ-2000. Monash University’s Micromon Genomics, a next-generation sequencing facility located in the university’s Biomedical precinct at the Clayton campus in Melbourne, provides sequencing services to Australian researchers, including DNA, RNA, single cell and customised applications. “This instrument precisely fits our yield requirements, giving us the flexibility and scope to complete both small and large projects, without the necessity to queue large numbers of samples before commencing sequencing runs,” Micromon Genomics’ NGS Manager Mr. Scott Coutts said. “Data quality is equal to or better than the data we currently generate on alternative platforms, as well as bringing about substantial service price reductions.”  MGI has a strong local support team based in Brisbane providing commercial support, technical training and after-sale services to Australia and New Zealand. To provide better product and service for users in  the region, MGI authorised Decode Science as the distributor for next generation sequencers and related products. MGI and DS jointly provide after sales applications and service support to new and existing units in the region, utilising MGI's dedicated local support team. MGI instruments are gaining more recognition from local scientists and researchers.  MGI has delivered over 1,000 sequencers to more than 300 users in 16 countries worldwide. 

Micromon Genomics

Micromon is a not-for-profit facility located in the Biomedical precinct at Monash University, Melbourne, Australia. As a specialist facility, Micromon offers expertise in DNA and RNA technologies where Sanger long-read sequencing and Next-Generation short-read sequencing form the key services, along with allied technologies. With more than 35 years of experience, Micromon has a long history of excellent project design and management, and a strong focus on personalised customer service and support.

More in the media

Customer Testimonial

"The MGI instrument enables us to provide our sequencing data at a much better cost per base and per read, both instrument and consumables than we could (have) ever achieved with our current instrumentation. MGI has been very responsive to our inquiries and very responsive to our requests for troubleshooting, product development, and application support." Micromon Genomics' NGS Manager Mr. Scott Coutts says.

BGI Genomics and Pryzm Health Form Strategic Partnership to Advance Precision Public Health

BGI Genomics and Pryzm Health Form Strategic Partnership

BGI Genomics and a digital health start-up, Pryzm Health (Pryzm), signed a Memorandum of Understanding on 14 May 2019 for collaboration to advance precision public health in Australia. With their complementary expertise and technology, BGI Genomics and Pryzm will develop foundational capabilities to drive equitable access to precision medicine approaches across the health system. This movement, termed precision public health, will enable more rapid diagnoses, improved efficiency, better patient outcomes and more economically-sustainable health practices. Pryzm is an innovative digital health start-up focused on guiding personal and clinical health decisions by accelerating diagnosis of rare and inherited diseases. The collaboration aims to improve the utility of cost-effective genomic testing for the clinic and lower the barriers for access to precision healthcare in Australia by harnessing the synergy between the complementary technologies of BGI Genomcs in genomics and Pryzm in the integration and analytics of genomic information and electronic health data. BGI Genomics, a subsidiary of BGI, provides a wide range of next generation sequencing services and a broad portfolio of genetic tests for medical institutions, research institutions and other public and private partners. 

Pryzm Health

Pryzm is a digital health company focused on identifying and accelerating patient diagnosis, particularly of rare and inherited diseases. Pryzm fulfils its mission by developing secure and clinically-compliant software to support phenotyping and phenotype analysis to serve patients and the healthcare industry. 

More in the Media
BGI Genomics & genomiQa sign wgs services agreement

BGI Genomics & genomiQa sign wgs services agreement

GenomiQa and BGI Genomics formed an agreement, on 25 March, on clinical whole genome cancer sequencing utilising BGI’s ISO15189 accredited laboratory sequencing facilities. Dr Bicheng Yang, Director of BGI Australia said, “We are really pleased with the growth of our sequencing services on DNBseqTM technology platform and the opportunity to support innovative companies like genomiQa. By working together with genomiQa, researchers and physicians can use whole genome analysis to unlock potential new treatments and support the best patient outcomes similar to the 'Immunotherapy Outcomes Predication' project we are working together on." genomiQa's CEO Colin Albert said, “We have been working with BGI on a number of research projects and validation studies to reach this exciting milestone. More importantly we will start to help patients who have only had access to comprehensive panels, where up to 38% of breast cancer patients may not have received the best treatment options, as actionable information was not available." genomiQa also intends to use BGI’s facility in Australia once it has completed the ISO 15189 accreditation process in the next 12 months. Keep reading

About genomiQa

genomiQa is a start-up company out of the QIMR Berghofer Medical Research Institute, which provides computational pipeline services to analyse whole genome data, DNA/RNA. The high-quality genomic pipeline was developed by founders Dr Nic Waddell and John Pearson and offered clinicians and companies high-quality analysis of genomic data to inform health care decisions.

Find out more

BGI's MGI Announces Early Access Customer of MGISEQ-T7

January 2019 - MGI, a subsidiary of BGI Group, announced WeGene, one of the largest companies providing direct-to-consumer genetics testing in China, as its first early access customer for the new ultra high-throughput sequencer, MGISEQ-T7, saying it has driven down sequencing cost to $5 per Gigabase, with exceptionally high accuracy. MGI also launched the MGI global sequencer user program to support collaborators to begin using MGISEQ-T7. MGI also announced a global partnership with Paragon Genomics, a leader in amplicon-based target enrichment and library preparation solutions for next-generation sequencing assays. To date MGI has reached a new milestone of 1,000 MGI sequencers installed in 16 countries. MGI's proprietary technologies include DNBseq™ patented gene sequencing technology and patterned array technology, BGI Australia reports.  Keep reading

MGISEQ-T7 Highest Throughput Sequencer Brings Power of Choice to the Market

MGISEQ-T7 Highest Throughput Sequencer Brings Power of Choice to the Market

BGI Research and Macquarie University Deepen Cooperation in Synthetic Biology

BGI Research & Macquarie University Deepen Cooperation

BGI-Research and the Macquarie University of Australia formally signed a cooperation agreement during the 7th International Yeast 2.0 and Synthetic Genomes Conference 2018 in Sydney, on 26th November. The two sides will jointly promote scientific research and education in synthetic biology, and focus on engineering bacteria transformation of natural products in synthetic biology. In the next five years, BGI Research and Macquarie University will fully leverage their resources to focus on bilateral cooperation in the fields of synthetic biology, metabolic engineering, and natural product synthesis. The two parties will work together with the goal to jointly opening new channels for talent training, to explore opportunities for industrialization of scientific research projects and drive related areas development in China and Australia. Keep reading

About Macquarie University

Founded in 1964, Macquarie University is a public research university located in Sydney. It has been given five stars by the international QS stars rating system in teaching, research, facilities, innovation and specialist subjects. Macquarie University is ranked among the top 1% of universities in the world.  

Find out more

BGI's MGI Launches its most powerful genetic sequencer

MGI launched its most powerful genetic sequencer in October 2018 MGISEQ-T7, built with innovative quadruple flowcell staging that allows simultaneous but independent operation of 1 to 4 flowcells in a single run. The MGI proprietary gene sequencing technology used in T7 delivers higher accuracy and improves efficiency through upgrades to the flowcell, fluid, and biochemical and optical system. T7 takes the production capacity of the sequencer to a new level with daily output of data up to 6Tb.

Upcoming Events

No upcoming events.

Subscribe Newsletter

Contact Us

We'd love to hear from you.

BGI Australia continuously seeks collaborative opportunities throughout Australia to maintain scientific excellence.

Inquiry: bgi-australia@genomics.cn


Privacy Collection Statement download here

Privacy Statement download here

BGI Australia

L6, CBCRC Building, 300 Herston Road, Herston, Queensland 4006, Australia

(07) 3362 0475

Hours

Monday - Friday: 9am - 5pm

Saturday & Sunday: Closed

Drop us a line!

Cancel

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.